210 related articles for article (PubMed ID: 30156148)
1. Individualized Tacrolimus Therapy for Pediatric Nephrotic Syndrome: Considerations for Ontogeny and Pharmacogenetics of CYP3A.
Sun JY; Xu ZJ; Sun F; Guo HL; Ding XS; Chen F; Xu J
Curr Pharm Des; 2018; 24(24):2765-2773. PubMed ID: 30156148
[TBL] [Abstract][Full Text] [Related]
2. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
Hesselink DA; Bouamar R; Elens L; van Schaik RH; van Gelder T
Clin Pharmacokinet; 2014 Feb; 53(2):123-39. PubMed ID: 24249597
[TBL] [Abstract][Full Text] [Related]
3. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 3A: ontogeny and drug disposition.
de Wildt SN; Kearns GL; Leeder JS; van den Anker JN
Clin Pharmacokinet; 1999 Dec; 37(6):485-505. PubMed ID: 10628899
[TBL] [Abstract][Full Text] [Related]
5. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
6. Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.
Bruckmueller H; Werk AN; Renders L; Feldkamp T; Tepel M; Borst C; Caliebe A; Kunzendorf U; Cascorbi I
Ther Drug Monit; 2015 Jun; 37(3):288-95. PubMed ID: 25271728
[TBL] [Abstract][Full Text] [Related]
7. Impact of
Huang L; Wang J; Yang J; Zhang H; Ni Y; Zhu Z; Wang H; Gao P; Wu Y; Mao J; Fang L
Pharmacogenomics; 2019 Oct; 20(15):1071-1083. PubMed ID: 31588879
[No Abstract] [Full Text] [Related]
8. CYP3A5 and CYP3A7 genetic polymorphisms affect tacrolimus concentration in pediatric patients with nephrotic range proteinuria.
Liu H; Xu Q; Huang W; Zhao Q; Jiang Z; Kuang X; Li Z; Sun H; Qiu X
Eur J Clin Pharmacol; 2019 Nov; 75(11):1533-1540. PubMed ID: 31401678
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus treatment in childhood refractory nephrotic syndrome: A retrospective study on efficacy, therapeutic drug monitoring, and contributing factors to variable blood tacrolimus levels.
Guo HL; Xu J; Sun JY; Li L; Guo HL; Jing X; Xu ZY; Hu YH; Xu ZJ; Sun F; Ding XS; Chen F; Zhao F
Int Immunopharmacol; 2020 Apr; 81():106290. PubMed ID: 32058933
[TBL] [Abstract][Full Text] [Related]
10. Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome.
Lu T; Zhu X; Xu S; Zhao M; Huang X; Wang Z; Zhao L
Pharm Res; 2019 Feb; 36(3):45. PubMed ID: 30719576
[TBL] [Abstract][Full Text] [Related]
11. The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients.
Madsen MJ; Bergmann TK; Brøsen K; Thiesson HC
Drugs R D; 2017 Jun; 17(2):279-286. PubMed ID: 28229376
[TBL] [Abstract][Full Text] [Related]
12. Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome.
Li L; Zhu M; Li DY; Guo HL; Hu YH; Xu ZY; Jing X; Chen F; Zhao F; Li YM; Xu J; Jiao Z
Int Immunopharmacol; 2021 Sep; 98():107827. PubMed ID: 34284341
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 3A polymorphisms and immunosuppressive drugs.
Thervet E; Legendre C; Beaune P; Anglicheau D
Pharmacogenomics; 2005 Jan; 6(1):37-47. PubMed ID: 15723604
[TBL] [Abstract][Full Text] [Related]
14. Temporary decrease in tacrolimus clearance in cytochrome P450 3A5 non-expressors early after living donor kidney transplantation: Effect of interleukin 6-induced suppression of the cytochrome P450 3A gene.
Enokiya T; Nishikawa K; Hamada Y; Ikemura K; Sugimura Y; Okuda M
Basic Clin Pharmacol Toxicol; 2021 Mar; 128(3):525-533. PubMed ID: 33248001
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model.
Huang L; Liu Y; Jiao Z; Wang J; Fang L; Mao J
Eur J Pharm Sci; 2020 Feb; 143():105199. PubMed ID: 31862313
[TBL] [Abstract][Full Text] [Related]
16. CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients.
Gijsen VM; van Schaik RH; Elens L; Soldin OP; Soldin SJ; Koren G; de Wildt SN
Pharmacogenomics; 2013 Jul; 14(9):1027-36. PubMed ID: 23837477
[TBL] [Abstract][Full Text] [Related]
17. Clinical aspects of tacrolimus use in paediatric renal transplant recipients.
Prytuła A; van Gelder T
Pediatr Nephrol; 2019 Jan; 34(1):31-43. PubMed ID: 29479631
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
Hesselink DA; van Schaik RH; van der Heiden IP; van der Werf M; Gregoor PJ; Lindemans J; Weimar W; van Gelder T
Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
20. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.
Anglicheau D; Legendre C; Beaune P; Thervet E
Pharmacogenomics; 2007 Jul; 8(7):835-49. PubMed ID: 18240909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
